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http:WHAT THIS PAPER ADDS
The impact of post-implantation syndrome (PIS) on the outcome of patients after elective endovascular
aneurysm repair (EVAR) is still unknown. In the present study PIS after EVAR was prospectively evaluated and its
association with various clinical and laboratory parameters, as well as the clinical outcome of the patients was
investigated. It was found that a systematic inﬂammatory response is observed in almost one third of the
patients after EVAR. For the ﬁrst time in the literature it has been shown that the intensity of the inﬂammation,
as assessed mainly by the post-operative high sensitivity C-reactive protein values, correlates with the presence
of a cardiovascular or any other adverse event during the ﬁrst 30 days after the procedure.Objectives: The aim was to prospectively evaluate post-implantation syndrome (PIS) after elective endovascular
aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs) and to investigate its association with clinical and
laboratory parameters and the clinical outcome of the patients.
Methods: From January 2010 till June 2013, 214 consecutive patients treated electively by EVAR for AAA were
prospectively included. PIS was deﬁned according to systemic inﬂammatory response syndrome criteria. Adverse
events included any major adverse cardiovascular events (MACE), acute renal failure, re-admission and death
from any cause.
Results: PIS was diagnosed in 77 (34%) patients. Pre-operative white blood cell (WBC) count values (p < .001),
endograft material (polyester) (p < .001), and heart failure (p ¼ .03) were independent predictors of PIS. Mean
post-operative temperature (p < .001), length of hospital (p < .001) and intensive care unit (p ¼ .008) stay, as
well as maximum post-operative WBC count (p < .001) and hs-CRP values (p < .001) were signiﬁcantly higher in
the PIS group. Post-operative hs-CRP (p ¼ .001) and duration of fever (p ¼ .02) independently predicted the
occurrence of MACE. Post-operative hs-CRP (p ¼ .004), maximum temperature (p ¼ .03), and the presence of PIS
(p ¼ .01) were independent predictors of an adverse event during the ﬁrst 30 days. A threshold of post-operative
hs-CRP value of 125 mg/L was highly associated with the occurrence of MACE, with a sensitivity of 82% and
speciﬁcity of 75%.
Conclusions: A systematic inﬂammatory response is observed in a signiﬁcant number of patients after EVAR. The
type of endograft material seems to play a signiﬁcant role in this inﬂammatory process. The intensity of
inﬂammation, as assessed mainly by the post-operative hs-CRP values, correlates with the presence of a
cardiovascular or any other adverse event during the ﬁrst 30 days after the procedure.
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Post-implantation syndrome (PIS) has been used to describe
a clinical entity characterized by systemic inﬂammation af-
ter endovascular repair of an abdominal aortic aneurysm
(EVAR).1 The impact of the syndrome on patient outcome is
still unknown. The post-operative inﬂammatory response
raises concerns of increased morbidity, especially in pa-
tients at high cardiovascular risk. In most cases, PIS is
176 E. Arnaoutoglou et al.generally well tolerated, but even then it may result in a
more demanding post-operative recovery leading to pro-
longed hospitalization, and thus it might be considered a
moderate complication of the procedure.2,3 Rarely, the in-
ﬂammatory process has been reported to lead to the
development of serious complications such as pulmonary
dysfunction, cardiovascular events, renal insufﬁciency, even
multisystem organ failure.4e7 However, in several large
EVAR papers the association of these clinical reactions with
PIS has not been yet reported.
In 2010, this group published some preliminary results of
40 consecutive EVAR patients, evaluating the association of
PIS with clinical and laboratory parameters.3 PIS was diag-
nosed in 35% of the patients. Patients with PIS showed
signiﬁcantly greater changes of inﬂammation marker levels,
including high sensitivity C-reactive protein (hs-CRP) and
interleukin 6 (IL-6), than the non-PIS group. PIS was also
associated with longer hospitalization. In another publica-
tion the readmission of ﬁve EVAR patients and one thoracic
EVAR (TEVAR) patient during the ﬁrst 30 days after the
procedure due to a systemic inﬂammatory response syn-
drome (SIRS) was reported.7 All these patients had PIS post-
operatively. It was concluded that in some patients, the
initial inﬂammatory response following EVAR is not always
benign and therefore patients developing an excessive in-
ﬂammatory response may need close surveillance. Other
groups have also investigated possible factors that may in-
ﬂuence PIS after EVAR. Voûte et al.8 found that polyester
stent grafts were independently associated with an
increased risk of PIS, while Moulakakis et al.9 conﬁrmed
these results in a later report. However, the association
between PIS and patient outcome, including cardiovascular
or other adverse events, has not been prospectively inves-
tigated in any study so far.
Based on the results of two previous studies, the hy-
pothesis that there might be a relationship between PIS
occurrence and patient outcome after EVAR was tested, and
the present study was designed to prospectively evaluate
PIS after elective endovascular aneurysm repair of abdom-
inal aortic aneurysm (AAA) and to investigate its association
with various clinical and laboratory parameters, as well as
the clinical outcome of the patients.METHODS
Deﬁnition
PIS fulﬁlls at least two of the SIRS criteria (i.e., fever and
leukocytosis).10 Therefore, PIS was deﬁned as the presence
of fever (persisting body temperature > 38 C lasting for
more than 1 day during hospitalization) and leukocytosis
(white blood cell count > 12.000/mL) with negative blood
culture results.Study sample
In a prospective study approved by the institutional review
committee, all patients having EVAR between January 2010
and June 2013 were eligible for inclusion. During this time,endovascular repair was offered to all suitable patients
according to the ESVS practice guidelines for the manage-
ment of AAA.11 Exclusion criteria included:
 Clinical and/or laboratory evidence of infection pre-
operatively, including leukocytosis (white blood cell
count [WBC] > 10.000/mL) and elevated body
temperature.
 Signs of gangrene.
 Previous trauma or surgery two months prior to
enrollment.
 Previous implantation of endoprosthesis.
 Any autoimmune disease or systemic inﬂammatory
condition.
 Any malignancy.
 Use of anti-inﬂammatory drugs, chemotherapeutic
agents, immunosuppressants, or anticoagulants.
Procedure
All patients were treated by the same surgical and anes-
thesiology team in a fully equipped operating room with the
patient under general anesthesia. Every effort was made to
follow the selection criteria recommended by the manu-
facturer of the stent graft, however, the surgeon’s decision
as to which device to use was based on the anatomical
characteristics of the proximal neck, the iliac artery conﬁg-
uration, and the presence of thrombus or calciﬁcation.
Systemic heparinization was achieved with 5,000 IU of
heparin. Every effort was made to deploy the endovascular
device just below the level of the lowest renal artery. The
stent grafts implanted were Endurant (Medtronic Inc, Santa
Rosa, CA, USA), Anaconda (Vascutek, a Terumo company,
Inchinnan, UK), Zenith (Cook Inc., Indianapolis, IN, USA),
Aorﬁx (Lombard Medical Technologies, Oxfordshire, UK),
Powerlink (Endologix, Irvine, California), and Excluder (W.L.
Gore & Associates, Flagstaff, AZ, USA). The material of the
ﬁrst four devices is polyester, while the last two devices are
made from ePTFE. All the devices were bifurcated systems.
All patients received antibiotic prophylaxis (teicoplanin
400 mg, and ceftriaxone 1 g) half an hour pre-operatively
and for the day of operation, as well as 3500 IU of low
molecular weight heparin (tinzaparin) from the ﬁrst post-
operative day until discharge. In all patients, de-
mographics, intra-operative and post-operative complica-
tions, the incidence of PIS, the diameter of the aneurysm,
the type of the graft deployed, the operation time, the
amount of contrast media administered (Optiray 320, Mal-
linckrodt Inc, St. Louis, MO, USA), and length of post-
operative stay, were recorded. Temperature was recorded
eight times daily for the duration of hospitalization. Blood
tests including troponin levels were measured on the ﬁrst
and third post-operative day and the day before discharge.
Post-operative pain was controlled with intravenous tra-
madol, while in cases of fever >38.5 C lasting more than 2
hours intravenous paracetamol (1 g) was administered.
According to the protocol no anti-inﬂammatory drugs
(steroids or non-steroids) were used during the post-
operative period. All patients presenting with fever during
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criteria, underwent a thorough work up for possible infec-
tion. If any of these tests revealed evidence of an early
pulmonary, urinary tract or any other kind of infection, the
patient was not considered to suffer from PIS. Patients were
discharged in the absence of any complications, with a body
temperature <37.5 C for at least 24 hours and a WBC
<12.000/mL.
Variables of interest
Demographics, risk factors, pre-operative medication,
maximum aneurysm diameter, contrast media used, dura-
tion of the procedure, type of endograft, the occurrence of
PIS, maximum temperature, peri-operative complications,
and duration of hospital stay were recorded for each pa-
tient. Adverse events included any major adverse cardio-
vascular events (MACE), acute renal failure, readmission,
and death by any cause. MACE was deﬁned as a composite
of death from cardiac causes, non-fatal acute myocardial
infarction (ST and non-ST), ischemic stroke, or transient
ischemic attack.12,13 Aneurysm volume was calculated from
the computed tomography using a workstation with dedi-
cated reconstruction software (3Mensio, Medical imaging
B.V., Bilthoven, The Netherlands) by the same operator. At
ﬁrst the total AAA volume from pre-operative computed
tomography angiography (CTA) was calculated. Further-
more, from CTA in the ﬁrst month, the amount of newly
formed thrombus was calculated by subtracting the
endograft volume and the pre-operative thrombus volume
from the total AAA volume.
Medication
All patients were on antiplatelet therapy (aspirin 100 mg
once daily) for at least 3 weeks prior to the procedure. Pre-
operative medications were continued immediately after
surgery. Patients who were enrolled and were already
receiving a statin continued their medication. For patients
not already on statin, atorvastatin (20 mg once daily) was
initiated at the screening visit.
Blood samples
Venous blood was collected, without tourniquet, pre-
operatively and at days 1 and 3 post-operatively. Full
blood cell counts (WBC and platelets) were measured in an
automated hematology analyzer (model SE-9500; Sysmex
Corporation, Kobe, Japan). A high sensitivity assay was used
for the determination of serum CRP levels (hs-CRP Beckman
Coulter, Miami, FL, USA). The serum CRP levels were
determined via the scatter of light produced by the for-
mation of immune complexes in the test solution (Beckman
Coulter, Immage Immunochemistry System). IL-6 was
determined by immunosorbent assays in duplicated sam-
ples according to the manufacturer’s instructions (Bender
MedSystems, Vienna, Austria). The detailed process has
been previously reported.3 In brief, serum and standard
samples were incubated into the micro wells of an enzyme
linked immunosorbent assay (ELISA) plate, coated with amouse monoclonal antibody against the corresponding
human molecule. During the incubation a bound complex of
antigeneantibody was formed. After the removal of the
unbound material, a mixture of streptavidineehorseradish
peroxidase (HRP) and a biotin-conjugated detector mono-
clonal antibody against the complex was added. Following
the incubation step, the excess unbound material was
removed and a substrate solution reactive with the HRP was
added. During a new incubation step, a colored product was
formed in proportion to the serum amount of IL-6. The
enzymatic reaction was stopped and the absorbance of the
colored product was measured at 450 nm. A standard curve
of various IL-6 concentrations is used for the determination
of IL-6 concentration in the tested sample. Troponin con-
centrations were measured by Immunolite 2000 troponin I,
a solid phase, two site chemiluminescent assay (Diagnostic
Products Corporation, Corporate Ofﬁces, Louisiana, USA).Statistical analysis
Since there was a lack of adequate data regarding the exact
frequency or the effect of PIS on adverse events rates after
EVAR, no reliable sample size estimation was feasible. In the
preliminary report, there was evidence of PIS in 35% of the
patients, while ﬁve of 148 EVAR patients in another report
from this group needed re-admission due to symptoms of
severe inﬂammation. Based on these rates and given
ﬁnancial restrictions, the study was designed to include
nearly 200 patients, so that the PIS group (z70 patients)
should have a relatively adequate size for estimation of
events differences. Data were expressed as
mean  standard deviation (SD) as appropriate, except for
non-Gaussian parameters, which were presented as median
(range). Comparisons of continuous variables were per-
formed by Student t test for normally distributed variables
and ManneWhitney U test for non-normally distributed
variables, while the chi-square test was used for categorical
variables. To assess the effect of the independent variables
observed within the study context, each one was initially
examined separately and the signiﬁcant predictors at level
p1 ¼ .25 were identiﬁed. These were used in a binary lo-
gistic regression model. The formerly non-signiﬁcant factors
were then considered again at level p2 ¼ .10. Interactions
between the main effects of the ﬁnal model were exam-
ined. The enter method with signiﬁcance level p3 ¼ .05 was
used to obtain p values and odds ratios for the main effects
and interactions. All analyses were carried out with SPSS
20.0 statistical package for Windows (IBM Corporation,
Armonk, New York).
RESULTS
A total of 214 patients (72.3  8.1 years, 97% males) were
included in the study. Stent deployment was technically
successful in all patients, with no intra-operative compli-
cations. PIS was diagnosed in 77 (36%) patients. Baseline
and peri-operative characteristics in patients with and
without PIS are shown in Table 1. In terms of baseline
characteristics, traditional cardiac risk factors were equally
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(7.5%) had MACE within 30 days of surgery, resulting in one
death. More speciﬁcally, 11 patients sustained a non-fatal
acute myocardial infarction, three a transient ischemic
attack, and one patient had a stroke. Four patients suffered
from acute renal failure, and four patients were readmitted
due to symptoms of severe inﬂammation.Predictors of PIS
Pre-operative WBC count values (p < .001), endograft
material (polyester) (p < .001), and heart failure (p ¼ .03)
were independent predictors of PIS, as shown by multiple
logistic regression analysis. For every 1,000 units increase
in pre-operative WBC count the chance of PIS increased by
95.5% (95% CI 50e255%). The use of polyester raised (95%
CI 5,3e29,5 times) the possibility of PIS 12 times
compared with the use of ePTFE. Patients suffering fromTable 1. Baseline characteristics and peri-operative clinical data of the
No PI
n ¼ 1
Age, years 72 
Male gender, n (%) 132 (9
BMI, kg/m2 27.7 
AAA diameter, cm 5.8 
AAA volume preop 195.4
Endoluminal thrombus pre-op 104.3
Patent IMA 99 (72
Inﬂammatory AAA 10 (7.
Risk factors
Hypertension, n (%) 118 (8
CAD, n (%) 66 (47
COPD, n (%) 58 (42
Smoking, n (%) 82 (59
CHF, n (%) 17 (12
Diabetes mellitus, n (%) 27 (19
Hyperlipidemia, n (%) 106 (7
Peri-operative characteristics
White blood cell count pre-op (  103/mL) 6.6 
White blood cell count post-op (max,  103/mL) 10 
hs-CRP preop (mg/L) 3.2 (0
hs-CRP post-op (max, mg/L) 88 
IL-6 pre-op (pg/mL) 5.2 (3
IL-6 post-op (max, pg/mL) 36.9 (
PLT pre-op 196.8
PLT post-op (max) 151.4
Duration of operation (min) 108 
Media contrast (mL) 151.6
Radiation Burden (mGym2) 2.1 (0
Radiation time (min) 21 
ICU stay (days) 0 (0e
Temperature maximum (C) 37.8 
Temperature duration (days) 0.78 
Days of stay (days) 3 (2e
Accessory renal artery covered 5 (3.6
Newly formed thrombus at ﬁrst month 64.6 
BMI ¼ body mass index; AAA ¼ abdominal aortic aneurysm; IMA
COPD ¼ chronic obstructive pulmonary disease; CHF ¼ congestiv
6 ¼ interleukin 6; PLT ¼ platelets.heart failure were three times (95% CI: 1.1e8.5 times)
more likely to have PIS than those who did not. The
endografts that were deployed are shown in Table 2. The
relationship between the different endografts deployed
and the occurrence of PIS is shown in Fig. 1A. 127 grafts
were made of polyester, and 87 were ePTFE. Endografts
made of polyester had signiﬁcantly higher rates of PIS
development than endografts made from ePTFE (polyester
group 52.8% vs. PTFE group 11.5%, p < .001) (Fig. 1B).
There were no differences recorded either in total pre-
operative AAA volume, pre-operative endoluminal
thrombus, or in the amount of newly formed thrombus
between the two groups (Fig. 2).PIS qualitative and quantitative characteristics
PIS characteristics are shown in Table 1. Mean post-
operative temperature (p < .001), length of hospitalstudy population.
S
37
PIS
n ¼ 77
p
8.1 72.9  8 .440
6.4) 74 (96.1) .927
5 28.5  5.5 .283
1.1 5.9  1.3 .558
 178.7 204.5  99.6 .767
 73.3 123.3  73.7 .190
.3) 53 (68.8) .639
3) 6 (7.8) .895
6.1) 69 (89.6) .462
.8) 45 (58.4) .149
.3) 42 (54.5) .086
.9) 47 (61) .865
.4) 15 (19.5) .164
.7) 18 (23.4) .527
7.4) 62 (80.5) .591
1.4 7.7  1.3 .101
2.5 15.9  3.8 <.001
.2e49) 4.3 (0.1e49) .374
61.6 132  63.3 <.001
.5e9.1) 6.4 (4.5e9.2) .640
21.3e66.8) 98.4 (63.6e126.8) <.001
 51.5 217.5  53.9 .006
 54 149.7  49.9 0.834
49.2 112.9  53 .521
 88.4 149  111.3 .852
.75e312) 2.1 (0.89e15.7) .351
16.2 23.2  15.2 .318
5) 0 (0e7) .008
.7 38.6  0.5 <.001
0.3 2.8  1.3 <.001
29) 6 (3e26) <.001
) 3 (3.9) .954
119.7 54.5  59 .620
¼ inferior mesenteric artery; CAD ¼ coronary artery disease;
e heart failure; hs-CRP: high sensitivity C reactive protein; IL-
Table 2. The stent grafts deployed in the two groups.
Total
n ¼ 214
No PIS
n ¼ 137
PIS
n ¼ 77
Endurant 108 52 56
Excluder 86 76 10
Anaconda 11 2 9
Zenith 7 6 1
Powerlink 1 1 0
Aorﬁx 1 0 1
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post-operative WBC count (p < .001), IL-6 (p < .001), and
hs-CRP values (p < .001) were signiﬁcantly higher in the PIS
group. In the vast majority (73/77, 94.8%) of patients in the
PIS group, the syndrome was evident from the ﬁrst post-
operative day. In all patients who sustained an adverse
event, PIS occurred before that event.
Inﬂuence on outcome
Major adverse cardiovascular events. None of the patients
was lost to follow up. During the ﬁrst 30 days, three of 137
patients (2.2%) in the non-PIS group had MACE, compared
with 13 out of 77 patients (16.8%) in the PIS group
(p < .001). More speciﬁcally, multiple logistic regression
analysis showed that the presence of coronary artery dis-
ease (p ¼ .01), post-operative hs-CRP (p ¼ .001), and
duration of fever (p ¼ .02) independently predicted the
occurrence of MACE. Patients suffering from CAD were 7.9
times (95% CI 1.6e38.6 times, p ¼ .011) more likely to
sustain MACE during the ﬁrst 30 days after the procedure.
For every additional day of post-operative fever after the
ﬁrst, the chance of MACE increased by 67.9% (95% CI 9.8e
260%, p ¼ .017), while for every 10 unit increase in the
post-operative hs-CRP the chance for MACE increased by
15% (95% CI 6e24%, p ¼ .001). The ROC curve analysis
showed that post-operative hs-CRP is an important value in
predicting the occurrence of MACE during the ﬁrst 30 days
after the procedure (area under the curve [AUC] 0.804;
p < .001; Fig. 3). A threshold value of 125 mg/L was highlyFigure 1. (A) The relation between the different endografts deployed
material the endografts made and its relation to PIS.associated with the occurrence of MACE, with a sensitivity
of 82% and speciﬁcity of 75%.
Adverse events. During the ﬁrst 30 days, four of 137 pa-
tients (2.9%) in the non-PIS group had an adverse event,
compared with 20 of 77 patients (25.9%) in the PIS group
(p < .001). Multiple logistic regression analysis showed that
hs-CRP post-operative values (p ¼ .004), post-implantation
syndrome (p ¼ .01), maximum temperature (p ¼ .02), and
history of smoking (p¼ .02) were independent predictors of
an adverse event during the ﬁrst 30 days after the proce-
dure. For every 10 unit rise in the value of post-operative
hs-CRP the chance of an adverse event increased by 12%
(95% CI 4e19%, p ¼ .004), while for every 1 degree rise in
maximum temperature the risk increased 3.1 times (95% CI
1.15e8.5 times higher, p ¼ .03). Patients diagnosed with
PIS after implantation were about ﬁve times (95% CI 1.5e
17.6, p ¼ .011) more likely to suffer an adverse event than
non-PIS patients, while smokers were about 4.3 times (95%
CI 1.25e15.1, p ¼ .02) more likely than non-smokers. The
ROC curve analysis showed that post-operative hs-CRP is an
important value in predicting the occurrence of an adverse
event during the ﬁrst 30 days after the procedure (area
under the curve [AUC] 0.79; p < .001, Fig. 4). A threshold
value of 125 mg/L was highly associated with the occur-
rence of an adverse event, with a sensitivity of 72% and
speciﬁcity of 75%.
DISCUSSION
This study shows that PIS affects nearly one third of patients
after EVAR for AAA. The reported incidence of PIS in the
literature varies widely from 14% to 60%.14e17 The lack of a
universally accepted deﬁnition may account for this varia-
tion. Some authors described PIS as the presence of fever
coinciding with an elevated serum CRP level, whereas
others regard it as the presence of fever combined with a
leukocytosis of different cut off values.8,9,14e17 This group
has proposed a deﬁnition of the syndrome according to
SIRS, as PIS actually fulﬁlls at least two of the SIRS criteriaand the occurrence of post-implantation syndrome (PIS). (B) The
Figure 2. Scatterplot showing (A) total abdominal aortic aneurysm volume in the two groups, (B) the volume of thrombus pre-operatively,
and (C) the newly formed thrombus after the ﬁrst post-operative month.
180 E. Arnaoutoglou et al.(fever and leukocytosis).18 In this study PIS was deﬁned as
the presence of fever (>38 C) and leukocytosis (>12.000/
mL). However, hs-CRP values were strongly related to the
presence of PIS and also emerged as an important predictor
of the 30 day outcome. Thus hs-CRP probably expresses the
intensity of the inﬂammatory response to endograft
deployment more consistently and reliably. It is likely that
this biomarker is more appropriate in deﬁning PIS than WBC
count and the deﬁnition of the syndrome might be based
mainly on hs-CRP values. Voûte et al.8 in their report
included CRP in the PIS deﬁnition and described PIS as fever
>38 C coinciding with an elevated serum CRP level above
10 mg/L. In any case, a universally accepted deﬁnition is
needed for use in everyday clinical practice and for
reporting standards when comparing different studies.
The cause of the inﬂammatory response after EVAR has
not been clearly deﬁned. It is important to identify theprimary event causing the inﬂammatory reaction. In open
AAA repair, a more pronounced elevated systemic inﬂam-
matory response has been observed than in EVAR, probably
due to the more signiﬁcant invasiveness of the procedure.19
The magnitude of this response may cover any effect of
other co-factors such as the type of the graft, although this
has not been studied so far. In EVAR cases, the amount of
contrast media, the endograft material, or the amount of
mural thrombus within the aneurysm sac have all been
implied as possible causative factors.8,9,20,21 The type of
anesthesia may also have a role by inﬂuencing the inﬂam-
matory cytokine response.22 As most of the patients
worldwide are operated on under general anesthesia, to
avoid any possible bias all patients in this study were
operated on under general anesthesia. In the present study
the contrast media used as well as the aneurysm’s
thrombus load were not correlated with PIS. This ﬁnding is
Figure 3. Major adverse cardiac event (MACE) plot of receiver
operating characteristic (ROC) curve for high sensitivity C-reactive
protein (hs-CRP) measured post-operatively, as well as for fever
duration. Diagonal segments are produced by ties.
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However, in the same report the authors showed that the
implantation of stent grafts based on polyester was inde-
pendently associated with a stronger inﬂammatory
response.8 Moulakakis et al.,9 observing a milder inﬂam-
matory activation in patients with a PTFE endograft, have
conﬁrmed this ﬁnding in a later report. In accordance withFigure 4. Adverse event plot of receiver operating characteristic
(ROC) curve for high sensitivity C-reactive protein (hs-CRP)
measured post-operatively, as well as maximum post-operative
temperature. Diagonal segments are produced by ties.these reports it was found that the use of polyester
endograft independently predicted PIS and was correlated
with a greater than 10 times higher risk for an inﬂammatory
response. Although other endograft parameters such as the
exoskeleton material (nitinol vs. stainless steel) have not
been investigated in the present study, the wide application
of these materials in cardiac and peripheral arterial stenting
with no reports of a remarkable inﬂammatory response
show that differences in the application of nitinol among
stent grafts is unlikely to inﬂuence PIS. Based on the three
studies mentioned above (450 patients overall), it is quite
obvious that the polyester fabric of the endograft can
predict the occurrence of PIS in more than 50% of patients.
Nevertheless, as shown in the multivariate analysis, some
other parameters seem to inﬂuence PIS occurrence and
perhaps the primary event causing the inﬂammatory reac-
tion is still unidentiﬁed and further study is therefore
required.
Coagulation disturbances after EVAR occur either as a
result of aneurysm sac thrombosis or by direct platelet
stimulation by the endograft material.23 A signiﬁcant
decrease in platelet count, an indirect index of platelet
activation and consumption, has been observed post-
operatively in a substantial proportion of EVAR patients.3,9
The amount of mural thrombus has also been proposed
to incur a role in the inﬂammatory response, as PIS initially
was linked with the release of inﬂammatory mediators from
the aneurysm thrombus.15,16 Kakisis et al.24 recently eval-
uated nearly 85 patients after EVAR and reported an as-
sociation between new onset thrombus and PIS. However,
Voûte et al.8 by investigating the relation of PIS with new
onset thrombus formation in 136 patients after EVAR did
not ﬁnd any correlation. This ﬁnding is in accordance with
the results here, as there was no difference either in total
pre-operative AAA volume and pre-operative endoluminal
thrombus, or in the amount of newly formed thrombus
between the two groups.
The effect of the syndrome on the outcome of the pa-
tients has not been well deﬁned. In most studies PIS is
generally well tolerated, showing a benign course during
the post-operative period.9 Most series have failed to
demonstrate any connection between PIS and post-
operative complications.9,14 However, no study so far has
focused on cardiovascular and other adverse events, by
prospectively evaluating the treated patients during the 30
day post-operative period. In many vascular centers, EVAR is
considered to be a quite simple procedure and most pa-
tients are discharged home the day after the procedure.
This could lead to non-awareness of some cardiovascular or
other adverse events that might happen during the post-
operative period, as patients might be referred to other
medical specialties or even hospitals. There is some evi-
dence that in some patients the initial inﬂammatory
response following EVAR is not always spontaneously
attenuated and could lead to the development of serious
complications even several days after the operation.7 For
example Chang et al.6 evaluated the effect of the inﬂam-
matory response on post-operative renal function after
182 E. Arnaoutoglou et al.endovascular repair of thoracoabdominal aneurysms and
found that the severity of the inﬂammation correlated with
post-operative renal dysfunction. In a previous publication
by the group, ﬁve EVAR patients and one TEVAR patient
who needed re-admission during the ﬁrst 30 days after the
procedure due to intense SIRS were reported.7 In the pre-
sent prospective study patients of the PIS group had
signiﬁcantly more adverse events during the ﬁrst month
after the procedure (9.3% vs. 1.8%). The intensity of the
inﬂammatory process, as shown from the post-operative
values of hs-CRP and the characteristics of fever, indepen-
dently predicted the occurrence of a cardiovascular or any
other adverse event during the ﬁrst month after EVAR.
Based on these results, it seems reasonable that patients
who develop an excessive inﬂammatory response post-
operatively might be better kept under surveillance for
the ﬁrst post-operative month. A cut off value of hs-CRP of
125 mg/dL in the immediate post-operative period could
probably distinguish those patients that need the extended
surveillance. Such a policy could lead to early identiﬁcation
of any cardiovascular or other adverse event that would
then be adequately treated.
The results of the present study certainly raise the
question about the need for PIS-speciﬁc treatment, focusing
on reducing the post-deployment inﬂammatory response.
Current literature provides scarce evidence and no estab-
lished algorithm concerning the type and duration of such
treatment. Some authors recommended aggressive routine
use of anti-inﬂammatory drugs while most others prefer a
more conservative approach.15,25 Akin et al.26 did not
observe any clinical beneﬁt of prolonging antibiotic treat-
ment beyond the day of endovascular intervention in PIS
patients. Bischoff et al.17 in a recent survey of vascular
surgery departments in Germany reported that 71% of the
vascular centers treated PIS with non-steroidal anti-inﬂam-
matory agents (NSAIDs). A recently published, prospective
randomized trial evaluated the effect of pre-operative high
dose glucocorticoid on PIS and reported an attenuated in-
ﬂammatory response with a faster recovery for those EVAR
patients treated with anti-inﬂammatory drugs.27 However,
the routine administration of drugs like steroids or NSAIDs is
of serious concern because of their side effects, especially in
patients with several comorbidities, including renal failure,
heart failure, or coronary artery disease.7 It is reasonable
that some patients presenting with an intense inﬂammatory
response, leading to prolonged hospitalization or even a
readmission, might beneﬁt from anti-inﬂammatory therapy.
Future studies might focus on the effect of routine or
symptom based anti-inﬂammatory therapy on the outcome
of patients developing PIS after EVAR.
These results should be interpreted in the light of certain
limitations, including the small number of cardiovascular
events and the effect of this on the statistical analysis. This
was not a randomized trial, though graft selection was
based strictly on anatomical criteria and not on any char-
acteristic of the inﬂammatory response. Furthermore, the
recording of detailed data on AAA anatomy such as the
length or angulation of the neck was not part of the presentprotocol. Although their potential effect on PIS cannot be
excluded, it was not considered that these parameters were
related to the inﬂammatory response after EVAR and they
have not been included in any PIS study so far. The lack of a
control group to better quantify the inﬂammatory response
should also be acknowledged. However, the creation of a
control group with AAA patients undergoing bilateral
femoral cut down alone without graft deployment would be
unethical. Inﬂammatory markers were only measured on
the ﬁrst and third post-operative day. Therefore, although
PIS is usually evident in the ﬁrst three post-operative days,
any rises in inﬂammatory markers occurring later may have
been missed by the study protocol.
In conclusion, a systematic inﬂammatory response is
observed in almost one third of patients after EVAR for
AAA. The type of endograft material (polyester) seems to
play a signiﬁcant role in this inﬂammatory process.
Although PIS is well tolerated in the majority of patients,
the intensity of the inﬂammation, as assessed mainly by
post-operative hs-CRP values, seems to correlate with the
presence of a cardiovascular or any other adverse event
during the ﬁrst 30 days after the procedure.
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